ConductScience.org, home

Paper356248

A double-blind multicentre comparison of diclofenac sodium and naproxen in osteoarthrosis of the hip.

Car A and 5 others. Scand J Rheumatol Suppl, 1978. Cited by 13 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. A double-blind multicentre comparison of diclofenac sodium and naproxen in osteoarthrosis of the hip. Papers, record 356248. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/356248

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A double-blind multicentre comparison of diclofenac sodium and naproxen in osteoarthrosis of the hip.
PubMed
Journal
Scand J Rheumatol Suppl
PubMed
Year
1978
PubMed
Publication types
Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
1.03
iCite
Revised in PubMed
2019-10-28
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Car AA
2Jajić II
3Krampac II
4Vitaus MM
5Zenić NN
6Zivković MM

Source PubMed

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DiclofenacMajor topic
Hip JointMajor topic
NaproxenMajor topic
OsteoarthritisMajor topic
PhenylacetatesMajor topic
Adult
Clinical Trials as Topic
Double-Blind Method
Drug Evaluation
Female
Humans
Male
Middle Aged

Source PubMed

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
27,790,020Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses.Open Access Rheumatol2013https://conductscience.org/library/papers/27790020PubMed
6,772,422Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin.Drugs1980https://conductscience.org/library/papers/6772422PubMed
6,488,707Outcome measurement in osteoarthritis clinical trials: the case for standardisation.Clin Rheumatol1984https://conductscience.org/library/papers/6488707PubMed
3,286,213Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.Drugs1988https://conductscience.org/library/papers/3286213PubMed
387,372Naproxen up to date: a review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states.Drugs1979https://conductscience.org/library/papers/387372PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/356248

GET https://conductscience.org/api/papers/v1/356248/authors